Integrated genomic characterization of endometrial carcinoma
- D. Levine, Gad Stacey B. Kristian Eric Andrey Carrie Mike Cyriac Getz Gabriel Cibulskis Lander Sivachenko Sougnez L, H. Sofia
- Biology, MedicineNature
- 1 May 2013
The genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours, and these features are classified into four categories: POLE ultramutated, microsatellite instability hypermutated, copy- number low, and copy-number high.
The Immune Landscape of Cancer
- V. Thorsson, David L. Gibbs, V. Jakrot
- 1 April 2018
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
It is shown that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways and linked with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogens pathway signatures to guide the use of targeted therapeutics.
Integrated Genomic Analyses of Ovarian Carcinoma
- D. Bell, A. Berchuck, E. Thomson
- 1 June 2011
It is reported that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1,BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes.
Comprehensive Characterization of Cancer Driver Genes and Mutations
- Matthew H. Bailey, C. Tokheim, A. Mariamidze
- 5 April 2018
Oncogenic Signaling Pathways in The Cancer Genome Atlas
- F. Sánchez-Vega, Marco Mina, A. Mariamidze
- 5 April 2018
Rethinking ovarian cancer: recommendations for improving outcomes
- Sebastian Vaughan, J. Coward, F. Balkwill
- MedicineNature Reviews. Cancer
- 1 October 2011
Nine major recommendations that should be taken to improve the outcome for women with ovarian cancer are outlined in this Opinion article.
Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer
- Zhen Zhang, R. Bast, D. Chan
- Biology, MedicineCancer Research
- 15 August 2004
These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer by demonstrating the sensitivity and specificity of a multivariate model combining the three biomarkers.
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
- T. Baba, P. A. Convery, S. Murphy
- 15 January 2009
Results show that CD133 expression in ovarian cancer is directly regulated by epigenetic modifications and support the idea thatCD133 demarcates an ovarian cancer-initiating cell population.